株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

ハンチントン病治療薬の世界市場:2017年〜2021年

Global Huntington's Disease Therapeutics Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 317294
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
ハンチントン病治療薬の世界市場:2017年〜2021年 Global Huntington's Disease Therapeutics Market 2017-2021
出版日: 2017年08月02日 ページ情報: 英文 86 Pages
概要

ハンチントン病とは進行性の神経変性障害で、神経細胞およびニューロンの破壊につながります。神経細胞の損傷によって、性格の変化や、気分変動、被刺激性、変容行動などが引き起こされます。この疾患の治療薬市場は、病態修飾薬に対する満たされない需要が高く、 今のところ唯一、Xenazineだけが認可を受けており、 様々な治療薬の承認適応症外使用が見受けられます。また、AUSTEDOの市場導入によって、市場成長に大きな影響を与え、市場力学を変革すると見られています。 世界のハンチントン病治療薬市場の2017〜2021年の年平均成長率(CAGR)は14.75%に達する見通しです。

当レポートでは、全世界のハンチントン病治療薬の市場について分析し、市場の概要や構造、市場規模の動向(今後5年間の予測値)、薬物クラス別・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・考察しております。

第1章 エグゼクティブ・サマリー

第2章 分析範囲

第3章 市場分析の手法

第4章 イントロダクション

  • 市場の概略

第5章 ハンチントン病について

第6章 市場環境

  • 市場概況
  • 市場規模とその予測
  • ファイブフォース分析

第7章 パイプライン

第8章 薬物クラス別の市場分析

  • 薬物クラス別市場
  • 抗ドーパミン作用薬
  • 抗けいれん薬
  • 抗精神病薬
  • 抗鬱剤
  • その他

第9章 地域別の分析

第10章 意思決定構造

第11章 市場の成長促進要因と課題

第12章 市場動向

第13章 ベンダー環境

  • 競争シナリオ

第14章 主要ベンダーの分析

  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Prana Biotechnology
  • Teva Pharmaceutical Industries
  • その他の有力ベンダー

第15章 付録

  • 略語集

図表

図表
  • Exhibit 01: Parts of brain affected by HD
  • Exhibit 02: Key facts about HD
  • Exhibit 03: Prevalence and incidence of HD
  • Exhibit 04: Neurotransmitter involved in pathogenesis of HD
  • Exhibit 05: Market snapshot
  • Exhibit 06: Global HD therapeutics market 2016-2021 ($ millions)
  • Exhibit 07: Opportunity analysis of global HD therapeutics market
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Pipeline landscape based on number of molecules 2016
  • Exhibit 10: HD: Key clinical trials
  • Exhibit 11: Segmentation of global HD therapeutics market by drug-class
  • Exhibit 12: Global HD therapeutics market share by drug-class
  • Exhibit 13: Antidopaminergics used in HD
  • Exhibit 14: Uses and side-effects of antidopaminergics
  • Exhibit 15: Global HD therapeutics market by antidopaminergics 2016-2021 ($ millions)
  • Exhibit 16: Pharmacologic approach for the treatment of chorea
  • Exhibit 17: Anticonvulsants used in HD
  • Exhibit 18: Uses and side-effects of anticonvulsants
  • Exhibit 19: Global HD therapeutics market by anticonvulsants 2016-2021 ($ millions)
  • Exhibit 20: Antipsychotics used in HD
  • Exhibit 21: Uses and side-effects of antipsychotics
  • Exhibit 22: Global HD therapeutics market by antipsychotics 2016-2021 ($ millions)
  • Exhibit 23: Symptoms of depression associated with HD
  • Exhibit 24: Global HD therapeutics market by antidepressants 2016-2021 ($ millions)
  • Exhibit 25: Symptoms of mania associated with HD
  • Exhibit 26: Global HD therapeutics market share by geography 2016 and 2021
  • Exhibit 27: Global HD therapeutics market revenue by geography 2016-2021
  • Exhibit 28: Global HD therapeutics market share by geography 2016-2021
  • Exhibit 29: HD therapeutics market scenario in different geographies
  • Exhibit 30: Market scenario in Americas
  • Exhibit 31: HD therapeutics market in Americas 2016-2021 ($ millions)
  • Exhibit 32: Market scenario in EMEA
  • Exhibit 33: HD therapeutics market in EMEA 2016-2021 ($ millions)
  • Exhibit 34: Market scenario in APAC
  • Exhibit 35: HD therapeutics market in APAC 2016-2021 ($ millions)
  • Exhibit 36: Planned clinical trials of iPS cell-based therapies
  • Exhibit 37: Competitive structure analysis of global HD therapeutics market 2016
  • Exhibit 38: F. Hoffmann-La Roche: Key highlights
  • Exhibit 39: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 40: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 42: H. Lundbeck: Key highlights
  • Exhibit 43: H. Lundbeck: Strength assessment
  • Exhibit 44: H. Lundbeck: Strategy assessment
  • Exhibit 45: H. Lundbeck: Opportunity assessment
  • Exhibit 46: Prana Biotechnology: Key highlights
  • Exhibit 47: Prana Biotechnology: Strength assessment
  • Exhibit 48: Prana Biotechnology: Strategy assessment
  • Exhibit 49: Prana Biotechnology: Opportunity assessment
  • Exhibit 50: Teva Pharmaceuticals: Key highlights
  • Exhibit 51: Teva Pharmaceuticals: Strength assessment
  • Exhibit 52: Teva Pharmaceuticals: Strategy assessment
  • Exhibit 53: Teva Pharmaceuticals: Opportunity assessment

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR14144

About Huntington's Disease Therapeutics

HD is an inherited condition that leads to destruction of nerve cells or neurons. The damage to nerve cells usually causes change in personality, mood swings, irritability and altered behavior. The global HD therapeutics market was witnessing a high unmet demand for disease modifying drug, in the presence of only one approved therapy, Xenazine, and the off-label use of various different therapeutics. The introduction of AUSTEDO in the market will have a significant impact on the market growth, thereby changing the market dynamics.

Technavio's analysts forecast the global huntington's disease therapeutics market to grow at a CAGR of 14.75% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global huntington's disease therapeutics market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Huntington's Disease Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Prana Biotechnology
  • Teva Pharmaceutical Industries

Other Prominent Vendors

  • Intellect Neurosciences
  • Horizon Pharma
  • Sangamo Therapeutics
  • Vertex Pharmaceuticals

Market driver

  • Early onset of disease symptoms, increases the demand for HD therapeutics
  • For a full, detailed list, view our report

Market challenge

  • Increase in alternative programs for management of mental disorders
  • For a full, detailed list, view our report

Market trend

  • Advances in biomedical sciences
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: HD: An introduction

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Pipeline

PART 08: Market segmentation by drug-class

  • Market scenario by drug-class
  • Antidopaminergics
  • Anticonvulsants
  • Antipsychotics
  • Antidepressants
  • Others

PART 09: Geographical segmentation

  • Market segmentation by geography
  • HD therapeutics market in Americas
  • HD therapeutics market in EMEA
  • HD therapeutics market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Advances in biomedical sciences
  • Focus on regenerative therapies for mental disorders
  • Rising public interest toward mental health

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Prana Biotechnology
  • Teva Pharmaceutical Industries
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations
Back to Top